WallStSmart

Johnson & Johnson (JNJ)vsStevanato Group SpA (STVN)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 7859% more annual revenue ($99.33B vs $1.25B). JNJ leads profitability with a 16.2% profit margin vs 11.3%. STVN appears more attractively valued with a PEG of 1.70. STVN earns a higher WallStSmart Score of 59/100 (C).

JNJ

Buy

54

out of 100

Grade: C-

Growth: 4.7Profit: 8.5Value: 3.7Quality: 5.5
Piotroski: 3/9Altman Z: 2.64

STVN

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 6.5Value: 6.7Quality: 7.0
Piotroski: 3/9Altman Z: 2.23
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for JNJ.

STVNUndervalued (+67.9%)

Margin of Safety

+67.9%

Fair Value

$48.58

Current Price

$15.53

$33.05 discount

UndervaluedFair: $48.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ3 strengths · Avg: 8.7/10
Market CapQuality
$682.52B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
26.6%8/10

Strong operational efficiency at 26.6%

Free Cash FlowQuality
$6.36B8/10

Generating 6.4B in free cash flow

STVN2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

JNJ4 concerns · Avg: 2.8/10
Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
43.0x2/10

Premium valuation, high expectations priced in

STVN2 concerns · Avg: 3.5/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 26.6%.

Bull Case : STVN

The strongest argument for STVN centers on Debt/Equity, Price/Book.

Bear Case : JNJ

The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 43.0x leaves little room for execution misses.

Bear Case : STVN

The primary concerns for STVN are PEG Ratio, Piotroski F-Score.

Key Dynamics to Monitor

JNJ profiles as a mature stock while STVN is a value play — different risk/reward profiles.

STVN carries more volatility with a beta of 0.80 — expect wider price swings.

STVN is growing revenue faster at 7.6% — sustainability is the question.

JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.

Bottom Line

STVN scores higher overall (59/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Stevanato Group SpA

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in innovative glass and polymer packaging solutions designed for injectable medications used by the pharmaceutical and biotechnology industries. With a steadfast focus on quality, sustainability, and the adoption of cutting-edge technologies, Stevanato is well-positioned to benefit from the burgeoning demand within the biopharmaceutical sector. The company’s dedication to enhancing the efficiency and reliability of drug administration makes it an attractive proposition for institutional investors looking for opportunities in healthcare innovation and sustainable growth.

Want to dig deeper into these stocks?